The Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus Pandemic: Part I. Increased Cardiovascular Disease Risk and the Importance of Atherogenic Dyslipidemia in Persons with the Metabolic Syndrome and Type 2 Diabetes Mellitus

Overview

Journal J Cardiometab Syndr

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2009 Jul 21

PMID 19614799

Citations 119

Authors

Henry N Ginsberg

Paul R Maccallum

Affiliations

Soon will be listed here.

Abstract

Both the metabolic syndrome (MS) and type 2 diabetes mellitus (T2DM) confer an increased risk of coronary heart disease and cardiovascular disease (CVD). As MS and T2DM become more prevalent, there will be an associated rise in the number of individuals with or at risk for CVD and its related disorders. One major underlying cause of CVD in patients with MS or T2DM is a characteristic form of atherogenic dyslipidemia. This article reviews the evidence that demonstrates that individuals with MS or T2DM are at increased risk for CVD and highlights atherogenic dyslipidemia as an important risk factor for the development of CVD in these individuals. In an accompanying article, current pharmacotherapies available for the management of atherogenic dyslipidemia in individuals with MS or T2DM are discussed.

Citing Articles

Exploring the potential link between human papillomavirus infection and coronary artery disease: a review of shared pathways and mechanisms.

Saha D, Dutta P, Rebello K, Shankar A, Chakraborty A Mol Cell Biochem. 2025; .

PMID: 40045143 DOI: 10.1007/s11010-025-05236-9.

Burden, determinants and treatment status of metabolic syndrome among older adults in India: a nationally representative, community-based cross-sectional survey.

Basu S, Thirunavukarasu A, Maheshwari V, Zode M, Hassan R BMJ Public Health. 2025; 1(1):e000389.

PMID: 40017860 PMC: 11812726. DOI: 10.1136/bmjph-2023-000389.

PCSK9 Expression in Vascular Smooth Muscle Cells: Role of Insulin Resistance and High Glucose.

Barale C, Tempesta G, Melchionda E, Morotti A, Frascaroli C, Danzero A Int J Mol Sci. 2025; 26(3).

PMID: 39940773 PMC: 11817378. DOI: 10.3390/ijms26031003.

Metabolic Health, Overweight or Obesity, and Lung Function in Older Australian Adults.

Opio J, Wynne K, Attia J, Hancock S, McEvoy M Nutrients. 2025; 16(24.

PMID: 39770878 PMC: 11676256. DOI: 10.3390/nu16244256.

Associations Between Dysregulation and Metabolic Syndrome in Youth and Adults.

Ametti M, Cheaito A, Frering H, Ades P, David C, Althoff R JAACAP Open. 2024; 2(3):161-169.

PMID: 39552819 PMC: 11562418. DOI: 10.1016/j.jaacop.2023.12.006.

References

Ford E . Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005; 28(7):1769-78. DOI: 10.2337/diacare.28.7.1769. View

Ford E . Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005; 28(11):2745-9. DOI: 10.2337/diacare.28.11.2745. View

Gaede P, Vedel P, Larsen N, Jensen G, Parving H, Pedersen O . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348(5):383-93. DOI: 10.1056/NEJMoa021778. View

Haffner S, Lehto S, Ronnemaa T, Pyorala K, Laakso M . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339(4):229-34. DOI: 10.1056/NEJM199807233390404. View

McNeill A, Rosamond W, Girman C, Golden S, Schmidt M, East H . The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005; 28(2):385-90. DOI: 10.2337/diacare.28.2.385. View

Lee C, Folsom A, Pankow J, Brancati F . Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation. 2004; 109(7):855-60. DOI: 10.1161/01.CIR.0000116389.61864.DE. View

Chapman M . Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther. 2006; 111(3):893-908. DOI: 10.1016/j.pharmthera.2006.02.003. View

Tirosh A, Rudich A, Shochat T, Tekes-Manova D, Israeli E, Henkin Y . Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med. 2007; 147(6):377-85. DOI: 10.7326/0003-4819-147-6-200709180-00007. View

Koskinen P, Manttari M, Manninen V, HUTTUNEN J, Heinonen O, FRICK M . Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992; 15(7):820-5. DOI: 10.2337/diacare.15.7.820. View

10.

Wyatt S, Winters K, Dubbert P . Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am J Med Sci. 2006; 331(4):166-74. DOI: 10.1097/00000441-200604000-00002. View

11.

Ford E . The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis. 2004; 173(2):309-14. DOI: 10.1016/j.atherosclerosis.2003.12.022. View

12.

Almdal T, Scharling H, Skov Jensen J, Vestergaard H . The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004; 164(13):1422-6. DOI: 10.1001/archinte.164.13.1422. View

13.

Wild S, Roglic G, Green A, Sicree R, King H . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5):1047-53. DOI: 10.2337/diacare.27.5.1047. View

14.

Hamman R, Wing R, Edelstein S, Lachin J, Bray G, Delahanty L . Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006; 29(9):2102-7. PMC: 1762038. DOI: 10.2337/dc06-0560. View

15.

Nordestgaard B, Benn M, Schnohr P, Tybjaerg-Hansen A . Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007; 298(3):299-308. DOI: 10.1001/jama.298.3.299. View

16.

Ballantyne C, Olsson A, Cook T, Mercuri M, Pedersen T, Kjekshus J . Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001; 104(25):3046-51. DOI: 10.1161/hc5001.100624. View

17.

Stamler J, Vaccaro O, Neaton J, Wentworth D . Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16(2):434-44. DOI: 10.2337/diacare.16.2.434. View

18.

Manninen V, Tenkanen L, Koskinen P, HUTTUNEN J, Manttari M, Heinonen O . Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992; 85(1):37-45. DOI: 10.1161/01.cir.85.1.37. View

19.

Turner R, Millns H, Neil H, Stratton I, Manley S, Matthews D . Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998; 316(7134):823-8. PMC: 28484. DOI: 10.1136/bmj.316.7134.823. View

20.

Ford E, Giles W, Dietz W . Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287(3):356-9. DOI: 10.1001/jama.287.3.356. View